Company: NIVFW
Filing Date: 2025-06-03
Form Type: 424B3
Source: 0001213900-25-050825
Chunk: 85

Company: NewGenIvf Group Ltd
Filing Date: 2025-06-03
Form: 424B3
Chunk 85
---
 management attention that would otherwise be available for development of its existing business and may not benefit NewGenIvf’s business strategy, may not generate sufficient revenues to offset the associated acquisition costs or may not otherwise result in the intended benefits. Any such transactions that NewGenIvf is able to complete may not result in any synergies or other benefits it had expected to achieve, which could result in impairment charges that could be substantial. In addition, NewGenIvf may not be able to find and identify desirable acquisition targets or business opportunities or be successful in entering into an agreement with any particular strategic partner. These transactions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect its results of operations. In addition, if the resulting business from such a transaction fails to meet NewGenIvf’s expectations, or it fails to successfully integrate such businesses into its own, its business, financial condition and results of operations may be adversely affected or it may be exposed to unknown risks or liabilities. Even when NewGenIvf identifies an appropriate acquisition or investment target, it may not be able to negotiate the terms of the acquisition or investment successfully, obtain financing for the proposed transaction, or integrate the relevant businesses into its existing business and operations. Strategic investments or acquisitions will involve risks commonly encountered in business relationships, including:

| ● | difficulties in assimilating and integrating the operations, personnel,      
 systems, data, technologies, products and services of the acquired business; |

| ● | inability of the acquired technologies, products or businesses to achieve  
 expected levels of revenue, profitability, productivity or other benefits; |

| ● | difficulties in retaining, training, motivating and integrating key 
 personnel;                                                          |

| ● | diversion of management’s time and resources from NewGenIvf’s 
 normal daily operations;                                      |

| ● | difficulties in maintaining uniform standards, controls, procedures 
 and policies within the combined organizations;                     |

| ● | difficulties in retaining relationships with customers, employees and 
 suppliers of the acquired business;                                   |

| ● | risks of entering markets in which NewGenIvf have limited or no prior 
 experience;                                                           |

| ● | regulatory risks, including remaining in good standing with existing                                                                
 regulatory bodies or receiving any necessary pre-closing or post-closing approvals, as well as being subject to new regulators with 
 oversight over an acquired business;                                                                                                |

| ● | assumption of contractual obligations that contain terms that are not                                                    
 beneficial to NewGenIvf, require it to license or waive